China Pharma Holdings vs Nutriband
China Pharma Holdings is the larger business, with $4.1m of revenue in fiscal 2025 against $2.0m for Nutriband (2.0 times as much). Nutriband grew faster (-4.8% against -8.5%). China Pharma Holdings kept more of each dollar of sales as profit: a net margin of -76.9% against -404.1%. Nutriband carries less debt relative to equity (0.5% against 14.5%).
| Latest fiscal year | China Pharma HoldingsCPHI, 2025 | NutribandNTRB, 2026 |
|---|---|---|
| Revenue | $4.1m | $2.0m |
| Revenue growth | -8.5% | -4.8% |
| Net income | −$3.2m | −$8.2m |
| Operating margin | -78.2% | -408.4% |
| Net margin | -76.9% | -404.1% |
| Return on equity | -20.9% | -125.6% |
| Free cash flow | $88,937 | −$5.1m |
| Cash | $345,112 | $4.6m |
| Total debt | $3.3m | $35,861 |
| Debt to equity | 14.5% | 0.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 221 | 500 |
| Market value | $24.7m | $77.9m |
| Price vs our value range | — | — |
| Moat score | 26 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |